2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Quote on Budget 2026 by Manish Jain, Managing Direct...
Quote on Union Budget 2026 by Mr. Ajit Mishra, SVP- ...
Quote on Budget 2026 by Ms. Amisha Vora,PL Capital -...
Union Budget 2026: India charts rare earth mineral-c...
Quote on Union Budget 2026 by Mr. Rajeev Radhakrishn...
NRIs can now invest in Indian stocks through Portfol...
Quote on Union Budget 2026 by Mr. Shubham Jain, Grou...
Union Budget 2026: Strengthening fisheries, animal h...
Mahindra's overall auto sales touch 1,04,309 units i...
Quote on Budget Reaction by Sandeep Chordia, COO, Ko...
